A Live-Attenuated HSV-2 ICP0(-) Virus Elicits 10 to 100 Times Greater Protection against Genital Herpes than a Glycoprotein D Subunit Vaccine

作者：Halford William P^*; Pueschel Ringo; Gershburg Edward; Wilber Andrew; Gershburg Svetlana; Rakowski Brandon

来源：PLos One, 2011, 6(3): e17748.

DOI：10.1371/journal.pone.0017748

Glycoprotein D (gD-2) is the entry receptor of herpes simplex virus 2 (HSV-2), and is the immunogen in the pharmaceutical industry's lead HSV-2 vaccine candidate. Efforts to prevent genital herpes using gD-2 subunit vaccines have been ongoing for 20 years at a cost in excess of $100 million. To date, gD-2 vaccines have yielded equivocal protection in clinical trials. Therefore, using a small animal model, we sought to determine if a live-attenuated HSV-2 ICP0(-) virus would elicit better protection against genital herpes than a gD-2 subunit vaccine. Mice immunized with gD-2 and a potent adjuvant (alum+monophosphoryl lipid A) produced high titers of gD-2 antibody. While gD-2-immunized mice possessed significant resistance to HSV-2, only 3 of 45 gD-2-immunized mice survived an overwhelming challenge of the vagina or eyes with wildtype HSV-2 (MS strain). In contrast, 114 of 115 mice immunized with a live HSV-2 ICP0(-) virus, 0 Delta NLS, survived the same HSV-2 MS challenges. Likewise, 0 Delta NLS-immunized mice shed an average 125-fold less HSV-2 MS challenge virus per vagina relative to gD-2-immunized mice. In vivo imaging demonstrated that a luciferase-expressing HSV-2 challenge virus failed to establish a detectable infection in 0 Delta DNLS-immunized mice, whereas the same virus readily infected naive and gD-2-immunized mice. Collectively, these results suggest that a HSV-2 vaccine might be more likely to prevent genital herpes if it contained a live-attenuated HSV-2 virus rather than a single HSV-2 protein.

• 出版日期2011-3-11